血液金属离子阈值识别金属对金属髋关节植入物患者不良金属碎屑反应风险:伯明翰髋表面置换与Corail-Pinnacle植入物的外部多中心验证研究
该外部多中心验证研究纳入3个欧洲中心710例患者的803例金属对金属髋关节置换术,应用既往制定的植入物特异性血液金属离子阈值区分有无不良金属碎屑反应(ARMD),发现各阈值曲线下面积、敏感度、特异度等 discriminatory 特征良好,且较监管机构固定阈值漏诊ARMD患者更少,作者推荐使用植入物特异性阈值管理此类患者。
要点
- 单侧BHR阈值2.15 μg/L钴的AUC为89.4%,敏感度78.9%、特异度86.7%、阳性预测值44.1%、阴性预测值96.9%。
- 双侧BHR阈值5.5 μg/L(钴或铬最大值)的AUC为89.2%,敏感度70.6%、特异度86.8%、阳性预测值54.5%、阴性预测值93.0%。
- 单侧Corail-Pinnacle阈值3.57 μg/L钴的AUC为76.9%,敏感度65.0%、特异度85.4%、阳性预测值24.5%、阴性预测值97.1%。
核心结论
- 外部多中心验证研究确认,血液金属离子水平低于新的植入物特异性阈值的患者,在金属对金属髋关节置换术后发生ARMD的风险低。
- 使用这些植入物特异性阈值时,与使用监管机构目前提出的阈值相比,漏诊的ARMD患者更少。
- 作者因此推荐在管理已接受金属对金属髋关节置换术的患者时使用植入物特异性血液金属离子阈值。
研究设计与样本
- 外部多中心验证研究,纳入3个欧洲中心710例患者的803例金属对金属髋关节置换术(323例单侧Birmingham髋表面置换、93例双侧Birmingham髋表面置换、294例单侧Corail-Pinnacle植入物)。
- 所有患者接受全血金属离子采样,分为ARMD组(导致翻修或影像学识别,n=75)和无ARMD组(n=635)。
- 应用既往制定的植入物特异性血液金属离子阈值,并使用受试者工作特征曲线分析确定各阈值的区分特征。
主要发现
- 单侧BHR阈值区分有无ARMD的曲线下面积为89.4%(95%CI 82.8%至96.0%),敏感度78.9%,特异度86.7%,阳性预测值44.1%,阴性预测值96.9%。
- 双侧BHR阈值区分有无ARMD的曲线下面积为89.2%(95%CI 81.3%至97.1%),敏感度70.6%,特异度86.8%,阳性预测值54.5%,阴性预测值93.0%。
- 单侧Corail-Pinnacle植入物阈值区分有无ARMD的曲线下面积为76.9%(95%CI 63.9%至90.0%),敏感度65.0%,特异度85.4%,阳性预测值24.5%,阴性预测值97.1%。
- 使用植入物特异性阈值时漏诊20例ARMD患者(占本系列患者的2.8%)。
- 使用监管机构固定阈值时漏诊更多ARMD患者:使用英国7 μg/L(钴和铬均为)阈值时漏诊35例(4.9%,p=0.0003),使用美国3 μg/L(钴和铬均为)阈值时漏诊21例(3.0%,p=1.0),使用美国10 μg/L(钴和铬均为)阈值时漏诊46例(6.5%,p<0.0001)。
关键数值与推荐
- 单侧BHR的植入物特异性阈值为2.15 μg/L钴。
- 双侧BHR的植入物特异性阈值为5.5 μg/L(钴或铬的最大值)。
- 单侧Corail-Pinnacle植入物的植入物特异性阈值为3.57 μg/L钴。
临床怎么用
- 作者推荐在管理已接受金属对金属髋关节置换术的患者时使用植入物特异性血液金属离子阈值。
- 研究证据等级为诊断性研究III级。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The authors of recent studies have reported newly devised implant-specific blood metal ion thresholds to predict adverse reactions to metal debris (ARMD) in patients who have undergone unilateral or bilateral metal-on-metal (MoM) hip arthroplasty. These thresholds were most effective for identifying patients at low risk of ARMD. We investigated whether these newly devised blood metal ion thresholds could effectively identify patients at risk of ARMD after MoM hip arthroplasty in an external cohort of patients. METHODS: We performed a validation study involving 803 MoM hip arthroplasties (323 unilateral Birmingham Hip Resurfacing [BHR], 93 bilateral BHR, and 294 unilateral Corail-Pinnacle implants) performed in 710 patients at 3 European centers. All patients underwent whole-blood metal ion sampling, and were divided into 2 groups: those with ARMD (leading to revision or identified on imaging; n = 75) and those without ARMD (n = 635). Previously devised implant-specific blood metal ion thresholds (2.15 μg/L of cobalt for unilateral BHR; 5.5 μg/L for the maximum of either cobalt or chromium for bilateral BHR; and 3.57 μg/L of cobalt for unilateral Corail-Pinnacle implants) were applied to the validation cohort, and receiver operating characteristic curve analysis was used to establish the discriminatory characteristics of each threshold. RESULTS: The area under the curve, sensitivity, specificity, and positive and negative predictive values for the ability of each implant-specific threshold to distinguish between patients with and without ARMD were, respectively, 89.4% (95% confidence interval [CI] = 82.8% to 96.0%), 78.9%, 86.7%, 44.1%, and 96.9% for unilateral BHR; 89.2% (CI = 81.3% to 97.1%), 70.6%, 86.8%, 54.5%, and 93.0% for bilateral BHR; and 76.9% (CI = 63.9% to 90.0%), 65.0%, 85.4%, 24.5%, and 97.1% for unilateral Corail-Pinnacle implants. Using the implant-specific thresholds, we missed 20 patients with ARMD (2.8% of the patients in this series). We missed more patients with ARMD when we used the fixed thresholds proposed by regulatory authorities: 35 (4.9%) when we used the U.K. threshold of 7 μg/L for both cobalt and chromium (p = 0.0003), 21 (3.0%) when we used the U.S. threshold of 3 μg/L for both cobalt and chromium (p = 1.0), and 46 (6.5%) when we used the U.S. threshold of 10 μg/L for both cobalt and chromium (p < 0.0001). CONCLUSIONS: This external multicenter validation study confirmed that patients with blood metal ion levels below new implant-specific thresholds have a low risk of ARMD after MoM hip arthroplasty. Using these implant-specific thresholds, we missed fewer patients with ARMD compared with when the thresholds currently proposed by regulatory authorities were used. We therefore recommend using implant-specific blood metal ion thresholds when managing patients who have undergone MoM hip arthroplasty. LEVEL OF EVIDENCE: Diagnostic Level III. See Instructions for Authors for a complete description of levels of evidence.
引用
- Matharu GS, Berryman F, Judge A, et al. Blood Metal Ion Thresholds to Identify Patients with Metal-on-Metal Hip Implants at Risk of Adverse Reactions to Metal Debris: An External Multicenter Validation Study of Birmingham Hip Resurfacing and Corail-Pinnacle Implants. J Bone Joint Surg Am. 2017. PMID: 28926382. doi:10.2106/JBJS.16.01568
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。